Klin Farmakol Farm. 2013;27(1):29-36

Roflumilast and COPD

Pavel Turčáni
Klinika nemocí plicních a tuberkulózy FN Brno

The main pathological process that underlies chronic obstructive pulmonary disease (COPD) is a non-infectious inflammation. As a

systemic inflammation, it not only affects the airways and lung parenchyma, but also gradually changes the patient's appearance and

behaviour. The treatment of COPD with roflumilast, a selective phosphodiesterase 4 (PDE4) inhibitor, is an example of phenotype-specific

treatment and represents a major progress for the group of patients in whom it is indicated. Roflumilast affects the mechanisms of

inflammation typical for COPD, improves lung function, and reduces the rate of prognostically significant exacerbations. Moreover, its

use leads to specific considerations about COPD phenotypes and the application of phenotype-specific treatment.

Keywords: chronic obstructive pulmonary disease, chronic non-infectious inflammation, roflumilast

Published: May 15, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Turčáni P. Roflumilast and COPD. Klin Farmakol Farm. 2013;27(1):29-36.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Halbert RJ, Natoli JL, Gano A, et al. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006; 28: 523-532. Go to original source... Go to PubMed...
    2. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotype. The future of COPD. Am J Respir Crit Care Med 2010; 182: 598-604. Go to original source... Go to PubMed...
    3. Miravitles M, Calle M, Soler-Catalu?a JJ. Clinical phenotypes of COPD. Identification, definition and implications for quidelines. Arch Bronchoconeumol 2012; 48: 86-98. Go to original source...
    4. Global initiatiative for chronic obstructive pulmonary disease. Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease (updated 2010), http://www.goldcopd.org/uploads/users/files/GOLDReport_April112011.pdf.
    5. Global initiatiative for chronic obstructive pulmonary disease. Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease (updated 2011), www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Feb21.pdf.
    6. Koblížek, Chlumský (ed.). Doporučený postup ČPFS pro diagnostiku a léčbu stabilní CHOPN [online]. Dostupný na www.pneumologie.cz/aktualne/doc/Standard%20verze%2021.1.pdf.
    7. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea and excercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-1012. Go to original source... Go to PubMed...
    8. Bakke PS, Ronmark E, Eagan T, et al. Recommendations for epidemiological studies on COPD. Eur Respir J 2011; 38: 1261-1277. Go to original source... Go to PubMed...
    9. CHOPN? Fixní kombinace! Praha: AstraZeneca Czech Republic s.r.o, [2011]. leták.
    10. Souhrn údajů o přípravku [online]. 2010-05-07 [cit. 2012-11-1]. Dostupný na WWW: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/001179/WC500095209.pdf.
    11. Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007; 62: 1081-1087. Go to original source... Go to PubMed...
    12. Rabe K. Roflumilast for the treatment of chronic obstructive pulmonary disease. Expert Rev Resp Med 2010; 4: 543-555. Go to original source... Go to PubMed...
    13. Pinner NA, Hamilton LA, Hughes A. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease. Clin Ther. 2012; 34: 56-66. Go to original source... Go to PubMed...
    14. Miravitles M, Soler-Catalu?a JJ, Calle M, et al. Spanish COPD Guidelines. Treatment of Stable COPD. Arch Bronchoconeumol 2012; 48: 247-257. Go to original source...
    15. Celli BR. Update on the management of COPD. Chest 2008; 133: 1451-1462. Go to original source... Go to PubMed...
    16. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline uptdate for the ACP, ACCP, ATS and ERS. Ann Intern Med 2011; 155: 179-191. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.